Photo from wikipedia
s of the 23rd National Congress of Digestive Diseases / Digestive and Liver Disease 49S2 (2017) e73–e223 e91 respectively (Table A). Both PMS response and PMS remission, at Wk 2,… Click to show full abstract
s of the 23rd National Congress of Digestive Diseases / Digestive and Liver Disease 49S2 (2017) e73–e223 e91 respectively (Table A). Both PMS response and PMS remission, at Wk 2, were significantly associated (p<0.0001) with clinical endpoints at Wk 8 (Table B). Similar results were obtained in TNFi-naïve and -experienced subpopulations. Conclusions: In pts with moderate to severe UC treated with tofacitinib 10 mg BID, tofacitinib demonstrated induction efficacy based on PMS as early as Wk 2, the first time point measured in this study. Efficacy at Wk 2 is a good predictor of efficacy at Wk 8, regardless of prior TNFi therapy. Pts who have not achieved remission or response at Wk 2 based on PMS may still achieve improvements in Mayo score at Wk 8. Acknowledgement: Funded by Pfizer Inc. References: [1] Sandborn WJ et al. J Crohns Colitis 2016;10(S1):S15
Journal Title: Digestive and Liver Disease
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!